Randomized trial: dexamethasone in hospitalized patients with Covid-19
20 Jul, 2020 | 08:18h | UTCCommentary: Trial data support dexamethasone, but not hydroxychloroquine, for COVID-19 – CIDRAP
Related Commentary on Twitter
A randomized controlled trial testing dexamethasone for Covid-19 (the RECOVERY trial) showed that, compared with usual care, this corticosteroid drug reduced 28-day mortality in hospitalized patients. #COVID19 #SARSCoV2
— NEJM (@NEJM) July 18, 2020